GlassScriptPhysician profile
Samah Mohiuddin
NPI 1336455112
$2,872.71
in general payments reported to CMS, 2019-2025
34 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $265 · 2021: $19.02 · 2022: $145 · 2023: $234 · 2024: $803 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.38 |
| Education | $403.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $962.95 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Genentech USA, INC. | $223.39 | 2019-2024 | Ocrevus |
| Abbvie INC. | $223.09 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $192.92 | 2019-2024 | |
| Lilly USA, LLC | $146.90 | 2019-2024 | Emgality |
| Edw Pharma, INC. | $107.22 | 2019 | |
| Ucb, INC. | $79.12 | 2019-2025 | Rystiggo |
| Biogen, INC. | $78.49 | 2019-2024 | Vumerity, Tysabri |
| Supernus Pharmaceuticals, INC. | $67.71 | 2019 | |
| Emd Serono, INC. | $65.51 | 2019 | |
| Sunovion Pharmaceuticals INC. | $65.15 | 2019-2020 | |
| Livanova USA, INC. | $64.43 | 2019-2020 | |
| Pfizer INC. | $50.95 | 2024 | |
| Mallinckrodt Enterprises LLC | $50.20 | 2019 | |
| Abbott Laboratories | $48.80 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.51 | 2019-2020 | |
| Eisai INC. | $47.25 | 2024 | |
| Tanabe Pharma America, INC. | $38.69 | 2020-2025 | Radicava |
| Lundbeck LLC | $33.39 | 2025 | Vyepti |
| Neurocrine Biosciences, INC. | $29.31 | 2020-2025 | |
| Neurelis, INC. | $27.05 | 2024 | Valtoco |
| Strongbridge US INC. | $27.04 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $25.65 | 2024 | Nuedexta |
| Ani Pharmaceuticals, INC. | $22.54 | 2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $20.60 | 2019 | |
| Merz North America, INC. | $19.03 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.24 | 2024 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2024 | Hyqvia |
| Harmony Biosciences LLC | $16.82 | 2024 | |
| Csl Behring | $16.58 | 2019 | |
| Celgene Corporation | $13.87 | 2022 | |
| Allergan, INC. | $13.51 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,925,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samah Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.